A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors - Join Clinical Trial NCTNCT06827613
How to Join This Clinical Trial - NCTNCT06827613
Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE1, PHASE2 - Safety and effectiveness study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06827613 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 8 locations. Find a study site near you:
Clinical Research Site
Los Angeles, California 90033 - United States
Status: RECRUITING
Clinical Research Site
Los Angeles, California 90095 - United States
Status: RECRUITING
Clinical Research Site
Boston, Massachusetts 02114 - United States
Status: RECRUITING
Clinical Research Site
Columbus, Ohio 43212 - United States
Status: RECRUITING
Clinical Research Site
Nashville, Tennessee 37203 - United States
Status: RECRUITING
Clinical Research Site
San Antonio, Texas 78229 - United States
Status: RECRUITING
Clinical Research Site
Vancouver, British Columbia V5Z 1K1 - Canada
Status: RECRUITING
Clinical Research Site
Toronto, Ontario M5G 2C4 - Canada
Status: RECRUITING
How to Enroll in This Study
To learn more about participating in this PHASE1, PHASE2 clinical trial for Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships